{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T13:24:22Z","timestamp":1776432262347,"version":"3.51.2"},"reference-count":118,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,7]]},"DOI":"10.7759\/cureus.87436","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:47:40Z","timestamp":1751896060000},"source":"Crossref","is-referenced-by-count":2,"title":["Genetic Influences and Targeted Treatments in Osteoporosis: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Furkan","family":"Zurel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Bux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aqeela","family":"Diveli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakaria","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00070","article-title":"New insights into monogenic causes of osteoporosis","volume":"10","author":"M\u00e4kitie RE","year":"2019","unstructured":"M\u00e4kitie RE, Costantini A, K\u00e4mpe A, Alm JJ, M\u00e4kitie O. New insights into monogenic causes of osteoporosis. Front Endocrinol (Lausanne). 2019, 10:70. 10.3389\/fendo.2019.00070","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.15781","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"322","author":"Ensrud KE","year":"2019","unstructured":"Ensrud KE, Crandall CJ. Bisphosphonates for postmenopausal osteoporosis. JAMA. 2019, 322:2017-8. 10.1001\/jama.2019.15781","journal-title":"JAMA"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.14231","article-title":"Novel insights into the complex architecture of osteoporosis molecular genetics","volume":"1462","author":"Saad FA","year":"2020","unstructured":"Saad FA. Novel insights into the complex architecture of osteoporosis molecular genetics. Ann N Y Acad Sci. 2020, 1462:37-52. 10.1111\/nyas.14231","journal-title":"Ann N Y Acad Sci"},{"key":"ref4","article-title":"Osteoporosis","author":"Porter JL","year":"2019","unstructured":"Porter JL, Varacallo M. Osteoporosis. StatPearls Publishing, Treasure Island, FL; 2019."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2003.08.009","article-title":"Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development","volume":"34","author":"Amizuka N","year":"2004","unstructured":"Amizuka N, Davidson D, Liu H, et al.. Signalling by fibroblast growth factor receptor 3 and parathyroid hormone-related peptide coordinate cartilage and bone development. Bone. 2004, 34:13-25. 10.1016\/j.bone.2003.08.009","journal-title":"Bone"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref7","unstructured":"GeneCardsSuite.  COL1A1 gene - collagen type I alpha 1 chain . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=COL1A1."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron R","year":"2013","unstructured":"Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2013, 19:179-92. 10.1038\/nm.3074","journal-title":"Nat Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000178","article-title":"Genetics of osteoporosis: searching for candidate genes for bone fragility","volume":"60","author":"Rocha-Braz MG","year":"2016","unstructured":"Rocha-Braz MG, Ferraz-de-Souza B. Genetics of osteoporosis: searching for candidate genes for bone fragility. Arch Endocrinol Metab. 2016, 60:391-401. 10.1590\/2359-3997000000178","journal-title":"Arch Endocrinol Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.070802","article-title":"Bone regeneration is regulated by wnt signaling","volume":"22","author":"Kim JB","year":"2007","unstructured":"Kim JB, Leucht P, Lam K, Luppen C, Ten Berge D, Nusse R, Helms JA. Bone regeneration is regulated by wnt signaling. J Bone Miner Res. 2007, 22:1913-23. 10.1359\/jbmr.070802","journal-title":"J Bone Miner Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.23287","article-title":"Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation","volume":"112","author":"Lin GL","year":"2011","unstructured":"Lin GL, Hankenson KD. Integration of BMP, Wnt, and notch signaling pathways in osteoblast differentiation. J Cell Biochem. 2011, 112:3491-501. 10.1002\/jcb.23287","journal-title":"J Cell Biochem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-020-01153-7","article-title":"RANKL as a target for the treatment of osteoporosis","volume":"39","author":"Matsumoto T","year":"2021","unstructured":"Matsumoto T, Endo I. RANKL as a target for the treatment of osteoporosis. J Bone Miner Metab. 2021, 39:91-105. 10.1007\/s00774-020-01153-7","journal-title":"J Bone Miner Metab"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62349-5","article-title":"Osteoporosis: now and the future","volume":"377","author":"Rachner TD","year":"2011","unstructured":"Rachner TD, Khosla S, Hofbauer LC. Osteoporosis: now and the future. Lancet. 2011, 377:1276-87. 10.1016\/S0140-6736(10)62349-5","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2014.04.016","article-title":"Anti-sclerostin antibodies: utility in treatment of osteoporosis","volume":"78","author":"Clarke BL","year":"2014","unstructured":"Clarke BL. Anti-sclerostin antibodies: utility in treatment of osteoporosis. Maturitas. 2014, 78:199-204. 10.1016\/j.maturitas.2014.04.016","journal-title":"Maturitas"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-020-00279-w","article-title":"Mechanisms of bone development and repair","volume":"21","author":"Salhotra A","year":"2020","unstructured":"Salhotra A, Shah HN, Levi B, Longaker MT. Mechanisms of bone development and repair. Nat Rev Mol Cell Biol. 2020, 21:696-711. 10.1038\/s41580-020-00279-w","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3254","article-title":"Building strong bones: molecular regulation of the osteoblast lineage","volume":"13","author":"Long F","year":"2011","unstructured":"Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2011, 13:27-38. 10.1038\/nrm3254","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1615\/critreveukargeneexpr.v19.i1.10","article-title":"Signaling networks that control the lineage commitment and differentiation of bone cells","volume":"19","author":"Soltanoff CS","year":"2009","unstructured":"Soltanoff CS, Yang S, Chen W, Li YP. Signaling networks that control the lineage commitment and differentiation of bone cells. Crit Rev Eukaryot Gene Expr. 2009, 19:1-46. 10.1615\/critreveukargeneexpr.v19.i1.10","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.M.01096","article-title":"A review of osteocyte function and the emerging importance of sclerostin","volume":"96","author":"Compton JT","year":"2014","unstructured":"Compton JT, Lee FY. A review of osteocyte function and the emerging importance of sclerostin. J Bone Joint Surg Am. 2014, 96:1659-68. 10.2106\/JBJS.M.01096","journal-title":"J Bone Joint Surg Am"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20031454","article-title":"Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist","volume":"199","author":"van Bezooijen RL","year":"2004","unstructured":"van Bezooijen RL, Roelen BA, Visser A, et al.. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004, 199:805-14. 10.1084\/jem.20031454","journal-title":"J Exp Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling AG","year":"2008","unstructured":"Robling AG, Niziolek PJ, Baldridge LA, et al.. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin. J Biol Chem. 2008, 283:5866-75. 10.1074\/jbc.M705092200","journal-title":"J Biol Chem"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2007.05.001","article-title":"Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction","volume":"5","author":"Tatsumi S","year":"2007","unstructured":"Tatsumi S, Ishii K, Amizuka N, et al.. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab. 2007, 5:464-75. 10.1016\/j.cmet.2007.05.001","journal-title":"Cell Metab"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1822","article-title":"Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery","volume":"28","author":"Jacome-Galarza CE","year":"2013","unstructured":"Jacome-Galarza CE, Lee SK, Lorenzo JA, Aguila HL. Identification, characterization, and isolation of a common progenitor for osteoclasts, macrophages, and dendritic cells from murine bone marrow and periphery. J Bone Miner Res. 2013, 28:1203-13. 10.1002\/jbmr.1822","journal-title":"J Bone Miner Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.4248\/BR201301003","article-title":"Osteoclasts: new insights","volume":"1","author":"Feng X","year":"2013","unstructured":"Feng X, Teitelbaum SL. Osteoclasts: new insights. Bone Res. 2013, 1:11-26. 10.4248\/BR201301003","journal-title":"Bone Res"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0854.2012.01395.x","article-title":"Membrane trafficking in osteoblasts and osteoclasts: new avenues for understanding and treating skeletal diseases","volume":"13","author":"Zhao H","year":"2012","unstructured":"Zhao H. Membrane trafficking in osteoblasts and osteoclasts: new avenues for understanding and treating skeletal diseases. Traffic. 2012, 13:1307-14. 10.1111\/j.1600-0854.2012.01395.x","journal-title":"Traffic"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/30756","article-title":"Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain","volume":"393","author":"Schroeter EH","year":"1998","unstructured":"Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998, 393:382-6. 10.1038\/30756","journal-title":"Nature"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/er.2016-1002","article-title":"Notch signaling and the skeleton","volume":"37","author":"Zanotti S","year":"2016","unstructured":"Zanotti S, Canalis E. Notch signaling and the skeleton. Endocr Rev. 2016, 37:223-53. 10.1210\/er.2016-1002","journal-title":"Endocr Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.05.010","article-title":"Targeting Notch degradation system provides promise for breast cancer therapeutics","volume":"104","author":"Liu J","year":"2016","unstructured":"Liu J, Shen JX, Wen XF, Guo YX, Zhang GJ. Targeting Notch degradation system provides promise for breast cancer therapeutics. Crit Rev Oncol Hematol. 2016, 104:21-9. 10.1016\/j.critrevonc.2016.05.010","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1210\/en.2012-1732","article-title":"Osteoblast lineage-specific effects of notch activation in the skeleton","volume":"154","author":"Canalis E","year":"2013","unstructured":"Canalis E, Parker K, Feng JQ, Zanotti S. Osteoblast lineage-specific effects of notch activation in the skeleton. Endocrinology. 2013, 154:623-34. 10.1210\/en.2012-1732","journal-title":"Endocrinology"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2014.01.023","article-title":"Notch1 and Notch2 expression in osteoblast precursors regulates femoral microarchitecture","volume":"62","author":"Zanotti S","year":"2014","unstructured":"Zanotti S, Canalis E. Notch1 and Notch2 expression in osteoblast precursors regulates femoral microarchitecture. Bone. 2014, 62:22-8. 10.1016\/j.bone.2014.01.023","journal-title":"Bone"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1359\/JBMR.040907","article-title":"Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6","volume":"19","author":"Holmen SL","year":"2004","unstructured":"Holmen SL, Giambernardi TA, Zylstra CR, et al.. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res. 2004, 19:2033-40. 10.1359\/JBMR.040907","journal-title":"J Bone Miner Res"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081235","article-title":"Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone","volume":"24","author":"Williams BO","year":"2009","unstructured":"Williams BO, Insogna KL. Where Wnts went: the exploding field of Lrp5 and Lrp6 signaling in bone. J Bone Miner Res. 2009, 24:171-8. 10.1359\/jbmr.081235","journal-title":"J Bone Miner Res"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2012.10.003","article-title":"LRP5 and LRP6 in development and disease","volume":"24","author":"Joiner DM","year":"2013","unstructured":"Joiner DM, Ke J, Zhong Z, Xu HE, Williams BO. LRP5 and LRP6 in development and disease. Trends Endocrinol Metab. 2013, 24:31-9. 10.1016\/j.tem.2012.10.003","journal-title":"Trends Endocrinol Metab"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1086\/338450","article-title":"A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait","volume":"70","author":"Little RD","year":"2002","unstructured":"Little RD, Carulli JP, Del Mastro RG, et al.. A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002, 70:11-9. 10.1086\/338450","journal-title":"Am J Hum Genet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1513066112","article-title":"Identification and characterization of an injury-induced skeletal progenitor","volume":"112","author":"Marecic O","year":"2015","unstructured":"Marecic O, Tevlin R, McArdle A, et al.. Identification and characterization of an injury-induced skeletal progenitor. Proc Natl Acad Sci U S A. 2015, 112:9920-5. 10.1073\/pnas.1513066112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1096\/fj.05-4221fje","article-title":"Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation","volume":"19","author":"Poole KE","year":"2005","unstructured":"Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, L\u00f6wik CW, Reeve J. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 2005, 19:1842-4. 10.1096\/fj.05-4221fje","journal-title":"FASEB J"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.12.4946-4955.2005","article-title":"Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling","volume":"25","author":"Ai M","year":"2005","unstructured":"Ai M, Holmen SL, Van Hul W, Williams BO, Warman ML. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass-associated missense mutations in LRP5 affect canonical Wnt signaling. Mol Cell Biol. 2005, 25:4946-55. 10.1128\/MCB.25.12.4946-4955.2005","journal-title":"Mol Cell Biol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1086\/318811","article-title":"Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein","volume":"68","author":"Brunkow ME","year":"2001","unstructured":"Brunkow ME, Gardner JC, Van Ness J, et al.. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001, 68:577-89. 10.1086\/318811","journal-title":"Am J Hum Genet"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.080512","article-title":"Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd","volume":"23","author":"Kubota T","year":"2008","unstructured":"Kubota T, Michigami T, Sakaguchi N, et al.. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J Bone Miner Res. 2008, 23:1661-71. 10.1359\/jbmr.080512","journal-title":"J Bone Miner Res"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero P","year":"1996","unstructured":"Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996, 11:337-49. 10.1002\/jbmr.5650110307","journal-title":"J Bone Miner Res"},{"key":"ref40","article-title":"[Osteoporosis]","volume":"39","author":"Hintze G","year":"2016","unstructured":"Hintze G, Graf D. [Osteoporosis]. Med Monatsschr Pharm. 2016, 39:228-34.","journal-title":"Med Monatsschr Pharm"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.5152\/eurjrheum.2016.048","article-title":"An overview and management of osteoporosis","volume":"4","author":"S\u00f6zen T","year":"2017","unstructured":"S\u00f6zen T, \u00d6z\u0131\u015f\u0131k L, Ba\u015faran N\u00c7. An overview and management of osteoporosis. Eur J Rheumatol. 2017, 4:46-56. 10.5152\/eurjrheum.2016.048","journal-title":"Eur J Rheumatol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2020.06.004","article-title":"Osteoporosis in older adults","volume":"104","author":"Johnston CB","year":"2020","unstructured":"Johnston CB, Dagar M. Osteoporosis in older adults. Med Clin North Am. 2020, 104:873-84. 10.1016\/j.mcna.2020.06.004","journal-title":"Med Clin North Am"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.04.005","article-title":"The genetic architecture of osteoporosis and fracture risk","volume":"126","author":"Trajanoska K","year":"2019","unstructured":"Trajanoska K, Rivadeneira F. The genetic architecture of osteoporosis and fracture risk. Bone. 2019, 126:2-10. 10.1016\/j.bone.2019.04.005","journal-title":"Bone"},{"key":"ref44","unstructured":"OMIM. Geroderma osteodysplast\u0131cum; GO. (2020). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/231070?search=gorab&amp;highlight=gorab."},{"key":"ref45","unstructured":"GeneCards. GORAB gene - Golgin, RAB6 interacting . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=GORAB."},{"key":"ref46","unstructured":"Genetics of osteogenesis imperfecta and phenotypic implications. (2014). Accessed. April 11, 2021: https:\/\/www.ajmc.com\/view\/genetics-of-osteogenesis-imperfecta-and-phenotypic-implications."},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-13-26","article-title":"Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity","volume":"13","author":"Korvala J","year":"2012","unstructured":"Korvala J, J\u00fcppner H, M\u00e4kitie O, et al.. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med Genet. 2012, 13:26. 10.1186\/1471-2350-13-26","journal-title":"BMC Med Genet"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-08044-6","article-title":"GORAB scaffolds COPI at the trans-Golgi for efficient enzyme recycling and correct protein glycosylation","volume":"10","author":"Witkos TM","year":"2019","unstructured":"Witkos TM, Chan WL, Joensuu M, et al.. GORAB scaffolds COPI at the trans-Golgi for efficient enzyme recycling and correct protein glycosylation. Nat Commun. 2019, 10:127. 10.1038\/s41467-018-08044-6","journal-title":"Nat Commun"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1038\/ng.252","article-title":"Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin","volume":"40","author":"Hennies HC","year":"2008","unstructured":"Hennies HC, Kornak U, Zhang H, et al.. Gerodermia osteodysplastica is caused by mutations in SCYL1BP1, a Rab-6 interacting golgin. Nat Genet. 2008, 40:1410-2. 10.1038\/ng.252","journal-title":"Nat Genet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207655","article-title":"Rab GTPases in osteoclastic bone resorption and autophagy","volume":"21","author":"Roy M","year":"2020","unstructured":"Roy M, Roux S. Rab GTPases in osteoclastic bone resorption and autophagy. Int J Mol Sci. 2020, 21:7655. 10.3390\/ijms21207655","journal-title":"Int J Mol Sci"},{"key":"ref51","unstructured":"Geroderma osteodysplast\u0131cum; GO. (1986). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/231070."},{"key":"ref52","unstructured":"OMIM. Osteoporosis. (2016). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/166710."},{"key":"ref53","unstructured":"GeneCardsSuite. CALCR gene - calcitonin receptor . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CALCR."},{"key":"ref54","unstructured":"OMIM. O\u2019Neill MJ. Osteoporosis-pseudoglioma Syndrome. (2013). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/259770."},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2017.03.044","article-title":"LRP5: From bedside to bench to bone","volume":"102","author":"Williams BO","year":"2017","unstructured":"Williams BO. LRP5: From bedside to bench to bone. Bone. 2017, 102:26-30. 10.1016\/j.bone.2017.03.044","journal-title":"Bone"},{"key":"ref56","unstructured":"OMIM. Low density lipoprotein receptor-related protein 5; LRP5. (1999). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/603506."},{"key":"ref57","unstructured":"OMIM. PDZ and LIM domain protein 4; PDLIM4. (1999). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/603422."},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-003-0035-1","article-title":"Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women","volume":"48","author":"Omasu F","year":"2003","unstructured":"Omasu F, Ezura Y, Kajita M, et al.. Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. J Hum Genet. 2003, 48:342-5. 10.1007\/s10038-003-0035-1","journal-title":"J Hum Genet"},{"key":"ref59","unstructured":"OMIM. Wingless-type MMTV integration site family, member 1; Wnt1. (1986). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/164820."},{"key":"ref60","unstructured":"GeneCardsSuite. WNT1 gene - Wnt family member 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl."},{"key":"ref61","unstructured":"OMIM. Transcription factor Sp7; Sp7. (2002). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/606633."},{"key":"ref62","unstructured":"GeneCardsSuite. SP7 gene - Sp7 transcription factor . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl."},{"key":"ref63","unstructured":"UniProt. CRTAP - Cartilage-associated protein precursor. (2018). Accessed. April 11, 2021: https:\/\/www.uniprot.org\/uniprot\/O75718."},{"key":"ref64","unstructured":"OMIM. Cartilage-associated protein; CRTAP. (2000). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/605497."},{"key":"ref65","unstructured":"OMIM. Collagen, type I, alpha-1\u202f; COL1A1. (2020). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/120150."},{"key":"ref66","unstructured":"OMIM. Collagen, type I, alpha-2\u202f; COL1A2. (2020). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/120160."},{"key":"ref67","unstructured":"OMIM. Peptidyl-prolyl isomerase B; PPIB. (2021). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/123841."},{"key":"ref68","unstructured":"GeneCardsSuite.  PPIB gene - peptidylprolyl isomerase B. (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=PPIB."},{"key":"ref69","unstructured":"OMIM. Prolyl 3-hydroxylase 1; P3H1. (2006). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/610339."},{"key":"ref70","unstructured":"GeneCardsSuite. P3H1 gene - prolyl 3-hydroxylase 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=P3H1."},{"key":"ref71","unstructured":"OMIM. FK506-binding protein 10; FKBP10. (2002). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/607063."},{"key":"ref72","unstructured":"Genetic and Rare Diseases Information Center. Bruck syndrome. (2021). Accessed. April 11, 2021: https:\/\/rarediseases.info.nih.gov\/diseases\/1029\/bruck-syndrome-1."},{"key":"ref73","unstructured":"OMIM. Serpin peptidase inhibitor, Clade H, member 1; SERPINH1. (1995). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/600943."},{"key":"ref74","unstructured":"GeneCardsSuite. SERPINH1 gene - Serpin family H member 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=SERPINH1."},{"key":"ref75","unstructured":"OMIM. Serpin peptidase inhibitor, Clade F, member 1; SERPINF1. (1994). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/172860."},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-397165-4.00007-1","article-title":"Collagen structure, folding and function","author":"Makareeva E","year":"2014","unstructured":"Makareeva E, Leikin S. Collagen structure, folding and function. Osteogenesis Imperfecta: A Translational Approach to Brittle Bone Disease. Shapiro JR, Byers PH, Glorieux FH, Sponseller PD (ed): Academic Press, New York, NY; 2014. 71-84. 10.1016\/B978-0-12-397165-4.00007-1"},{"key":"ref77","unstructured":"OMIM. cAMP response element-binding protein 3-like 1; CREB3L1. (2015). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/616215."},{"key":"ref78","unstructured":"GeneCardsSuite. CREB3L1 gene - CAMP responsive element binding protein 3 like 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=CREB3L1."},{"key":"ref79","unstructured":"OMIM. Plastin 3; PLS3. (1998). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/300131."},{"key":"ref80","unstructured":"UniProt. PLS3 - plastin-3. (2021). Accessed. April 11, 2021: https:\/\/www.uniprot.org\/uniprot\/P13797."},{"key":"ref81","unstructured":"OMIM. Interferon-induced transmembrane protein 5; IFITM5. (2012). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/614757."},{"key":"ref82","unstructured":"GeneCardsSuite. IFITM5 gene - interferon induced transmembrane protein 5. (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=IFITM5."},{"key":"ref83","unstructured":"OMIM. Secreted protein, acidic, cysteine-rich; SPARC. (SPARC [Internet]. www.omim.org). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/182120."},{"key":"ref84","unstructured":"OMIM. Transmembrane protein 38B; TMEM38B. (2007). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/611236."},{"key":"ref85","unstructured":"NCBI. TMEM176A transmembrane protein 176A [Homo sapiens (human)]. (2021). Accessed. April 11, 2021: https:\/\/www.ncbi.nlm.nih.gov\/gene?Db=gene&amp;Cmd=DetailsSearch&amp;Term=55365."},{"key":"ref86","unstructured":"OMIM. Bone morphogenetic protein 1; BMP1. (1990). Accessed. April 11, 2021: https:\/\/www.omim.org\/entry\/112264."},{"key":"ref87","unstructured":"GeneCardsSuite. BMP1 Gene - Bone Morphogenetic Protein 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=BMP1."},{"key":"ref88","unstructured":"GeneCardsSuite. ESR1 gene - estrogen receptor 1 . (2020). Accessed. April 11, 2021: https:\/\/www.genecards.org\/cgi-bin\/carddisp.pl?gene=ESR1."},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1038\/nature14878","article-title":"Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture","volume":"526","author":"Zheng HF","year":"2015","unstructured":"Zheng HF, Forgetta V, Hsu YH, et al.. Whole-genome sequencing identifies EN1 as a determinant of bone density and fracture. Nature. 2015, 526:112-7. 10.1038\/nature14878","journal-title":"Nature"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.1242\/dev.02171","article-title":"The homeoprotein engrailed 1 has pleiotropic functions in calvarial intramembranous bone formation and remodeling","volume":"133","author":"Deckelbaum RA","year":"2006","unstructured":"Deckelbaum RA, Majithia A, Booker T, Henderson JE, Loomis CA. The homeoprotein engrailed 1 has pleiotropic functions in calvarial intramembranous bone formation and remodeling. Development. 2006, 133:63-74. 10.1242\/dev.02171","journal-title":"Development"},{"key":"ref91","unstructured":"Genecards Database. GeneALaCart - GeneCards batch queries. (2021). Accessed. April 11, 2021: https:\/\/genealacart.genecards.org\/."},{"key":"ref92","article-title":"Micro RNA: an early diagnostic marker for osteoporosis in post-menopausal women","volume":"69","author":"Baig R","year":"2019","unstructured":"Baig R, Murad R, Rehman R. Micro RNA: an early diagnostic marker for osteoporosis in post-menopausal women. J Pak Med Assoc. 2019, 69:1406-7.","journal-title":"J Pak Med Assoc"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26525-y","article-title":"Circulating microRNAs as potential diagnostic biomarkers for osteoporosis","volume":"8","author":"Mandourah AY","year":"2018","unstructured":"Mandourah AY, Ranganath L, Barraclough R, et al.. Circulating microRNAs as potential diagnostic biomarkers for osteoporosis. Sci Rep. 2018, 8:8421. 10.1038\/s41598-018-26525-y","journal-title":"Sci Rep"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-18670-7","article-title":"Associations between VDR gene polymorphisms and osteoporosis risk and bone mineral density in postmenopausal women: a systematic review and meta-analysis","volume":"8","author":"Zhang L","year":"2018","unstructured":"Zhang L, Yin X, Wang J, et al.. Associations between VDR gene polymorphisms and osteoporosis risk and bone mineral density in postmenopausal women: a systematic review and meta-analysis. Sci Rep. 2018, 8:981. 10.1038\/s41598-017-18670-7","journal-title":"Sci Rep"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2015.1007123","article-title":"Polymorphisms in VDR gene in Tunisian postmenopausal women are associated with osteopenia phenotype","volume":"18","author":"Sassi R","year":"2015","unstructured":"Sassi R, Sahli H, Souissi C, Sellami S, Ben Ammar El Gaaied A. Polymorphisms in VDR gene in Tunisian postmenopausal women are associated with osteopenia phenotype. Climacteric. 2015, 18:624-30. 10.3109\/13697137.2015.1007123","journal-title":"Climacteric"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-012-2072-3","article-title":"Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis","volume":"40","author":"Horst-Sikorska W","year":"2013","unstructured":"Horst-Sikorska W, Dytfeld J, Wawrzyniak A, et al.. Vitamin D receptor gene polymorphisms, bone mineral density and fractures in postmenopausal women with osteoporosis. Mol Biol Rep. 2013, 40:383-90. 10.1007\/s11033-012-2072-3","journal-title":"Mol Biol Rep"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.3390\/medicina49040028","article-title":"Association between polymorphisms of VDR, COL1A1, and LCT genes and bone mineral density in Belarusian women with severe postmenopausal osteoporosis","volume":"49","author":"Marozik P","year":"2013","unstructured":"Marozik P, Mosse I, Alekna V, et al.. Association between polymorphisms of VDR, COL1A1, and LCT genes and bone mineral density in Belarusian women with severe postmenopausal osteoporosis. Medicina (Kaunas). 2013, 49:177-84. 10.3390\/medicina49040028","journal-title":"Medicina (Kaunas)"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.3109\/13697137.2013.856401","article-title":"Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis","volume":"17","author":"Shen H","year":"2014","unstructured":"Shen H, Xie J, Lu H. Vitamin D receptor gene and risk of fracture in postmenopausal women: a meta-analysis. Climacteric. 2014, 17:319-24. 10.3109\/13697137.2013.856401","journal-title":"Climacteric"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2006.04.016","article-title":"Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis","volume":"39","author":"Fang Y","year":"2006","unstructured":"Fang Y, Rivadeneira F, van Meurs JB, Pols HA, Ioannidis JP, Uitterlinden AG. Vitamin D receptor gene BsmI and TaqI polymorphisms and fracture risk: a meta-analysis. Bone. 2006, 39:938-45. 10.1016\/j.bone.2006.04.016","journal-title":"Bone"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2015.04.002","article-title":"Association of Taq I, Fok I and Apa I polymorphisms in vitamin D receptor (VDR) gene with leprosy","volume":"76","author":"Neela VS","year":"2015","unstructured":"Neela VS, Suryadevara NC, Shinde VG, et al.. Association of Taq I, Fok I and Apa I polymorphisms in vitamin D receptor (VDR) gene with leprosy. Hum Immunol. 2015, 76:402-5. 10.1016\/j.humimm.2015.04.002","journal-title":"Hum Immunol"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1155\/2006\/921694","article-title":"BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis","volume":"22","author":"Zintzaras E","year":"2006","unstructured":"Zintzaras E, Rodopoulou P, Koukoulis GN. BsmI, TaqI, ApaI and FokI polymorphisms in the vitamin D receptor (VDR) gene and the risk of osteoporosis: a meta-analysis. Dis Markers. 2006, 22:317-26. 10.1155\/2006\/921694","journal-title":"Dis Markers"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-48126-1_15#DOI","article-title":"Current and emerging treatment of osteoporosis","author":"Tafaro L","year":"2020","unstructured":"Tafaro L, Napoli N. Current and emerging treatment of osteoporosis. Practical Issues in Geriatrics. Falaschi P, Marsh D (ed): Springer, Cham; 2020. 257-72. 10.1007\/978-3-030-48126-1_15#DOI"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200109)44:9<2201::aid-art374>3.0.co;2-e","article-title":"The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis","volume":"44","author":"Frith JC","year":"2001","unstructured":"Frith JC, M\u00f6nkk\u00f6nen J, Auriola S, M\u00f6nkk\u00f6nen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001, 44:2201-10. 10.1002\/1529-0131(200109)44:9&lt;2201::aid-art374&gt;3.0.co;2-e","journal-title":"Arthritis Rheum"},{"key":"ref104","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony S","year":"2001","unstructured":"Morony S, Capparelli C, Sarosi I, Lacey DL, Dunstan CR, Kostenuik PJ. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res. 2001, 61:4432-6.","journal-title":"Cancer Res"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(91)90499-o","article-title":"Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice","volume":"64","author":"Soriano P","year":"1991","unstructured":"Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991, 64:693-702. 10.1016\/0092-8674(91)90499-o","journal-title":"Cell"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1172\/JCI116032","article-title":"Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice","volume":"90","author":"Boyce BF","year":"1992","unstructured":"Boyce BF, Yoneda T, Lowe C, Soriano P, Mundy GR. Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest. 1992, 90:1622-7. 10.1172\/JCI116032","journal-title":"J Clin Invest"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13867","article-title":"Pharmacology of bisphosphonates","volume":"85","author":"Cremers S","year":"2019","unstructured":"Cremers S, Drake MT, Ebetino FH, Bilezikian JP, Russell RG. Pharmacology of bisphosphonates. Br J Clin Pharmacol. 2019, 85:1052-62. 10.1111\/bcp.13867","journal-title":"Br J Clin Pharmacol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2005.20.12.2274","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004","volume":"20","author":"Bekker PJ","year":"2005","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS, et al.. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. 2004. J Bone Miner Res. 2005, 20:2275-82. 10.1359\/jbmr.2005.20.12.2274","journal-title":"J Bone Miner Res"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.08.008","article-title":"Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability","volume":"49","author":"Bellido T","year":"2011","unstructured":"Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: preservation of osteoblast and osteocyte viability. Bone. 2011, 49:50-5. 10.1016\/j.bone.2010.08.008","journal-title":"Bone"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3138","article-title":"The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2-\u03b1]pyridin-3-yl)-ethyl-bisphosphonate)","volume":"32","author":"Lawson MA","year":"2017","unstructured":"Lawson MA, Ebetino FH, Mazur A, et al.. The pharmacological profile of a novel highly potent bisphosphonate, OX14 (1-fluoro-2-(imidazo-[1,2-\u03b1]pyridin-3-yl)-ethyl-bisphosphonate). J Bone Miner Res. 2017, 32:1860-9. 10.1002\/jbmr.3138","journal-title":"J Bone Miner Res"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1517\/14728220902841961","article-title":"Wnt signaling as a therapeutic target for bone diseases","volume":"13","author":"Hoeppner LH","year":"2009","unstructured":"Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009, 13:485-96. 10.1517\/14728220902841961","journal-title":"Expert Opin Ther Targets"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li X","year":"2009","unstructured":"Li X, Ominsky MS, Warmington KS, et al.. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009, 24:578-88. 10.1359\/jbmr.081206","journal-title":"J Bone Miner Res"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag KG","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, et al.. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017, 377:1417-27. 10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1016\/s0304-419x(03)00005-2","article-title":"Caught up in a Wnt storm: Wnt signaling in cancer","volume":"1653","author":"Giles RH","year":"2003","unstructured":"Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003, 1653:1-24. 10.1016\/s0304-419x(03)00005-2","journal-title":"Biochim Biophys Acta"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1016\/j.afos.2018.03.002","article-title":"Romosozumab for the treatment of osteoporosis","volume":"4","author":"McClung MR","year":"2018","unstructured":"McClung MR. Romosozumab for the treatment of osteoporosis. Osteoporos Sarcopenia. 2018, 4:11-5. 10.1016\/j.afos.2018.03.002","journal-title":"Osteoporos Sarcopenia"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2009.04.044","article-title":"The discovery of novel calcium sensing receptor negative allosteric modulators","volume":"19","author":"Balan G","year":"2009","unstructured":"Balan G, Bauman J, Bhattacharya S, et al.. The discovery of novel calcium sensing receptor negative allosteric modulators. Bioorg Med Chem Lett. 2009, 19:3328-32. 10.1016\/j.bmcl.2009.04.044","journal-title":"Bioorg Med Chem Lett"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.09.028","article-title":"An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation","volume":"46","author":"Kumar S","year":"2010","unstructured":"Kumar S, Matheny CJ, Hoffman SJ, et al.. An orally active calcium-sensing receptor antagonist that transiently increases plasma concentrations of PTH and stimulates bone formation. Bone. 2010, 46:534-42. 10.1016\/j.bone.2009.09.028","journal-title":"Bone"},{"key":"ref118","unstructured":"NHS. A study of MK5442 in the treatment of osteoporosis. (2009). Accessed. April 11, 2021: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/research-summaries\/a-study-of-mk5442-in-...."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/381004-genetic-influences-and-targeted-treatments-in-osteoporosis-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T13:47:50Z","timestamp":1751896070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/381004-genetic-influences-and-targeted-treatments-in-osteoporosis-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":118,"URL":"https:\/\/doi.org\/10.7759\/cureus.87436","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,7]]}}}